S
ilicosis is a severe and irreversible lung inflammatory disease caused by inhalation of free crystalline silica, which afflicts millions of workers in hazardous occupations and continues to be one of the most important occupational health illnesses in the world (1, 2) . The prevalence of silicosis is higher in countries of low and middle income, often because of inadequate adherence to safety and surveillance protocol (2) . In Brazil, only in the Minas Gerais state, .4500 gold-mining workers were reported to have silicosis (3) . Silicosis is characterized by inflammation followed by an intense fibrotic granulomatous response in the chronic phase, and despite the therapeutic arsenal currently available, there is no effective treatment for silicosis (4, 5) .
IL-13 is a Th2 cytokine that has a key role in many inflammatory diseases and appears to contribute to the development of pulmonary fibrosis and formation of granuloma (6) by a mechanism dependent on its ability to act directly on lung fibroblasts and mononuclear cells/macrophages (7, 8) . It is known that IL-13 binds to two chains, IL-13Ra1 and IL-13Ra2. IL-13Ra1 chain is a low-affinity receptor that forms a heterodimer with the IL-4Ra chain to form a high-affinity IL-13R and mediates signal transduction through the JAK-STAT-6 pathway (9) . IL-13Ra2 chain binds to IL-13 with high affinity but was shown to act as a decoy receptor in mice (10) . IL-13R subunits are expressed on a variety of immune and nonimmune cells (8, (11) (12) (13) (14) (15) . A therapeutic strategy for specifically targeting the profibrotic activity of IL-13 in the lung involves a fusion protein comprised of human IL-13, which recognizes and binds to the murine receptors of this cytokine, and a mutated form of Pseudomonas exotoxin (IL-13-PE38QQR or IL-13-PE) (16) . This fusion protein has been shown to be highly toxic to IL-13R-positive cells (16, 17) , but no adverse side effects associated with chronic administration of IL-13-PE have been reported (18) .
Taking into consideration the absence of an effective therapy for fibrogenic diseases such as silicosis, in this study, we examined the effect of intranasal administration of IL-13-PE on silica-induced chronic lung inflammation in mice.
Materials and Methods

Animals
Male Swiss Webster mice (18-20 g ) were obtained from the Oswaldo Cruz Foundation breeding colony and kept with controlled room temperature (22-25˚C) and a 12-h (6:00 AM-6:00 PM) light/dark cycle. All of the procedures involving care and use of animals in this study were in accordance with the guidelines of the Committee on Use of Laboratory Animals of the Oswaldo Cruz Foundation (CEUA-license L-034/09).
Sigma Chemical Co, St. Louis, MO; particle size 0.5-10 mm) diluted in sterile saline (0.9% NaCl). All of the analyses were performed 28 and 43 d postsilica challenge. Animals received an intranasal administration of a 200 ng/dose IL-13-PE, dissolved in 10 ml PBS containing 0.25% human serum albumin (PBS-HSA), every other day from days 21-27 after silica challenge. Animals were divided randomly into the following experimental groups: control group (n = 8), silica and PBS-HSA group (n = 8), and silica and IL-13-PE group (n = 8).
Lung histology
The left lung and the mediastinal draining lymph node (dissected free from adjacent connective tissue) were fixed in Milloning buffer solution (pH 7.4) with 4% paraformaldehyde for 48 h to preserve tissue architecture. Routine histological techniques were used to paraffin-embed samples, and 4-mm sections were stained with H&E or Picrosirius. Lung morphometric analysis was performed by an integrating eyepiece with a coherent system consisting of a grid with 100 points and 50 lines (known length) (19) coupled to a light microscope (Olympus BX50; Olympus) connected to a video camera (DEI-750; Optronics Engineering). The camera output was processed and examined by image analyzer software Image-Pro Plus Version 4. Silica crystals were quantitatively analyzed, in 10 independent fields, with a light microscope (Olympus BX50; Olympus) equipped with polarizing attachment for detecting birefrigent particles and Image-Pro Plus Version 4. The results were expressed as number of pixels per micrometers squared of tissue.
Immunohistochemistry
Left lung samples were examined for immunohistochemical localization of IL-4Ra, IL-13Ra1, IL-13Ra2 receptors, extracellular matrix components (laminin and fibronectin), a-SMA (a-smooth muscle actin), and F4/80. The Abs were obtained from the following sources: anti-IL-4Ra (AF530) and anti-IL-13Ra2 (AF539) from R&D Systems (Minneapolis, MN); anti-IL13Ra1 (849680) from Abcam (Cambridge, U.K.); anti-a-SMA (A2547) from Sigma-Aldrich (St. Louis, MO); and anti-mouse F4/80 (MCA497G) from AbD Serotec (Kidlington, U.K.). Secondary Abs conjugated with HRP were all obtained from R&D Systems. Immunostains of paraffin-embedded lung sections were performed as previously described (20) .
Quantification of lung collagen
Right lung was homogenized in Tris-HCl 0.05 M and NaCl 1 M containing protease inhibitor (Hoffmann-La Roche) (pH 7.4). Total soluble collagen was extracted overnight at room temperature and quantitated using the Sircol kit (Biocolor, Newton Abbey, U.K.). The results were expressed as milligrams collagen per right lung.
ELISA analysis
Murine TNF-a, TGF-b, macrophage inflammatory protein (MIP)-1a (CCL-3), MIP-2 (CXCL-2), macrophage-derived chemokine (MDC/CCL22), and thymus activation regulated chemokine (TARC/CCL17) levels were measured in right lung samples by means of ELISA technique as previously described (21) . Reagents from a commercial DuoSet kits (R&D Systems) were used following the instructions of the manufacturer. The cytokine levels were normalized to total protein levels measured using Bradford assay and expressed as nanograms of cytokine per milligram of protein.
Invasive assessment of respiratory mechanics
Airway reactivity was assessed as a change in airway function after challenge with aerosolized methacholine in a FinePoint R/C Buxco Platform (Buxco Research System). Mice were anesthetized with nembutal (60 mg/kg), and the neuromuscular activity was blocked with bromide pancuronium (1 mg/kg). Tracheostomized animals were mechanically ventilated and lung function was assessed. The trachea was cannulated and the cannula connected to a pneumotachograph.
Airflow and transpulmonary pressure were recorded with a Buxco pulmonary mechanics processing system (Buxco Electronics, Sharon, CT), which calculated resistance (cmH 2 O.s/ml) and dynamic lung compliance (mL/cmH 2 O) in each breath cycle. Elastance was calculated as the inverse of compliance values. All signals were analog-to-digital converted (Buxco Analogical/Digital Converter; Buxco Electronics). Animals were allowed to stabilize for 5 min, and increasing concentrations of methacholine (3-27 mg/ml) were aerosolized for 5 min each. Baseline pulmonary parameters were assessed with aerosolized PBS.
Lung fibroblast culture
The whole lung was removed from mice, 7 d after silica challenge, and gently dispersed on steel mesh followed by enzymatic digestion with collagenase 1A (Sigma-Aldrich) for 2 h at 37˚C. Dispersed cells were submitted to a continuous Percoll gradient (GE Healthcare) to eliminate free silica particles and then placed in DMEM medium containing 20% of FBS, 1% penicillin-streptomycin at 37˚C, and 5% CO 2 . The cultured cells were serially passaged a total of three times to have a pure population of lung fibroblasts (,95% 
Lung epithelial cell culture
A human lung carcinoma epithelial cell line A549 (ATCC CCL-185; American Type Culture Collection) was used. Cells were cultured in DMEM supplemented with 10% FBS, 100 UI/ml streptomycin, and 100 mg/ml penicillin at 37˚C in a 5% CO 2 -humidified incubator. For activation assays, cells were added to 24-well plates (5 3 10 4 cells/well) and, after 24 h, treated with IL-13-PE (200 and 400 ng/ml) for 1 h. Four replicate wells were assayed for IL-8 using ELISA DuoSet kits (R&D Systems) after stimulation with silica particles (300 mg/ml).
MTT assay
The cells were added to 96-well plates (2 3 10 4 cells/well) in serum-free DMEM, allowed to attach for 1.5 h and then incubated with IL-13-PE (200 and 400 ng/ml) 1 h before stimulation with silica particles (30-300 mg/ml). After 24 h, supernatant was discarded, and 20 ml MTT solution (5 mg/ml) was added to the cells or cell-free blank wells followed by 180 ml 10% FBS DMEM. Cell were incubated for 4 h at 37˚C with 5% CO 2 , 95% air. Plates were centrifuged at 1500 3 g for 3 min at 4˚C, 150 ml DMSO added and after 15 min, at room temperature, the OD of the wells was determined using a plate reader at 540 nm.
Apoptosis detection by TUNEL assay
The detection of apoptotic cells was performed in lung tissue sections using an in situ cell death detection kit (TACS 2TdT-DAB In Situ Apoptosis Detection Kit; Trevigen, Gaithersburg, MD) following the manufacturer's instructions. Briefly, paraffin sections were deparaffinized and rehydrated before permeabilization with Proteinase K, for 15 min at room temperature, followed by immersion in quenching solution for 5 min. After washing, samples were covered with TdT labeling reaction mix, incubated for 1 h at 37˚C, and after addition of TdT stop buffer, they were incubated with Strep-HRP solution (TACS 2TdT-DAB InSitu Apoptosis Detection Kit; Trevigen, Gaithersburg, MD) for 10 min. Cobalt cation was used in the labeling reaction for optimization. Samples were immersed in diaminobenzidine for 5 min and then washed with deionized water. Tissue was counterstained with methyl-green and prepared for viewing in light microscopy (3400).
Statistic analysis
Statistical analysis was done with one-way ANOVA followed by NewmanKeuls-Student test. The two-way ANOVA was also performed, followed by Bonferroni posttest for lung function analyses. The p values , 0.05 were considered statistically significant for both tests.
Results
Experimental silicosis in mice is associated with IL-13 generation and elevated pulmonary expression of IL-13Rs
Although IL-13 has been strongly implicated in numerous inflammatory and fibrotic conditions, there are limited data on the putative involvement of this Th2 cytokine in silicosis. Our findings from ELISA assessment of lung homogenates obtained 7, 14, and 28 d after nasal instillation of silica in mice revealed significant elevations in IL-13 levels at days 14 and 28 postchallenge, as compared with mice challenged with silica vehicle (0.9% saline) (Fig. 1A) . To determine if the upregulation of IL-13 levels was accompanied by significant changes in the expression of IL-13Rs, immunohistochemistry analysis was performed on lung tissue sections obtained from mice 28 d after silica or vehicle challenge. The representative photomicrography of lung sections immune-stained for the IL-4Ra chain revealed a constitutive expression of this protein following saline challenge (Fig. 1B) , which was further increased in lung sections obtained from silicotic mice (Fig. 1E) . In contrast, the immune staining for IL-13Ra1 and IL-13Ra2 was not apparent in the negative controls (Fig. 1C, 1D , respectively)
The Journal of Immunologyand was overexpressed in lung sections from animals exposed to silica (Fig. 1F, 1G , respectively). Quantitative morphometric analysis confirmed that there was a marked overexpression of IL-4Ra ( Fig. 1H ), IL-13Ra1 ( Fig. 1I ) and IL-13Ra2 ( Fig. 1G ) as compared with the respective negative control groups.
Intranasal IL-13-PE treatment significantly reduced silica-induced pulmonary granuloma formation and fibrosis
Having showed that IL-13 levels were elevated in lungs from silicotic mice, we evaluated whether intranasal IL-13-PE therapy could attenuate the fibrotic responses elicited by silica instillation. As illustrated in Fig. 2 , silicotic mice developed a severe inflammatory response with granuloma formation and fibrotic tissue. In contrast, the lung of silicotic mice that received 200 ng/dose intranasal IL-13-PE treatment between days 21 and 27 after silica instillation exhibited a clear decrease of inflammatory leukocytes and the greatest reduction of fibrotic response caused by silica challenge. These data were confirmed by morphometric analysis as shown in Fig. 2G , in which the IL-13-PE therapy was able to reduce 70% of area occupied by granuloma.
Considering the relevance of knowledge about action time of IL-13-PE therapy, we decided to perform analysis 15 d after the last administration of IL-13-PE. Our data showed that on day 43 postsilica challenge, the inflammatory process was still very intense with coalescent granuloma and exacerbated fibrosis. Surprisingly, we noted that IL-13-PE treatment was still effective because there were reduced numbers of inflammatory cells, smaller granulomas, and markedly less fibrosis (Fig. 2E, 2F ), which was confirmed by morphometric analysis (Fig. 2H) .
Quantitative morphometric analysis of whole lung samples from silicotic mice showed a marked increase in IL-4Ra, IL-13Ra1, and IL-13Ra2 protein expression (Table I) . Moreover, IL-13-PE therapy significantly decreased IL-13R expression, and the greatest reduction was observed in IL-13Ra2 protein expression. 
IL-13-PE treatment increased the clearance of silica particles
The presence of silica particles in the lung is very important due to the potential effect of residual particles in triggering and development of pulmonary fibrotic response. Our findings from polarized light microscopy revealed the presence of numerous small crystals that tend to be granular and blue bright in lung tissue from silicotic mice (Fig. 3A) . However, a marked decrease in the number of silica particles was observed in animals treated with IL-13-PE from days 21-27 (Fig. 3B) . Quantitative data are shown in Fig. 3C .
A disorganization of a regular lymph node structure and a granuloma-like cell accumulation were detected in silica-challenged mice (Fig. 3D ) by H&E staining, as compared with controls ( Fig.  3E) . A more intense response was detected in the lymph nodes of from IL-13-PE-treated silicotic mice (Fig. 3F) . Silica particles can be drained by the lymphatic system to the lymph nodes (22) . Morphological analysis of lung mediastinal lymph node of silicachallenged animals revealed the presence of silica particles localized inside the lymphoid follicles (Fig. 3G) . Treatment with IL-13-PE led to an increase in the number of particles in the lymph node, though not significant (Fig. 3H) . Quantitative data are shown in Fig. 3I .
IL-13-PE therapy significantly reduced lung function and airway hyperreactivity caused by silica particle instillation Airway hyperreactivity (AHR) following inhalation with methacholine is a persistent feature of chronic asthma and allergic response in mice (23, 24) , although this phenomenon is poorly understood in pulmonary silicosis. As shown in Fig. 4 , basal levels of airway resistance and dynamic elastance of lung measured in silicotic mice were increased when compared with control mice at 28 d postsilica challenge. After methacholine inhalation (3-27 mg/ml), silicotic mice exhibited both increased airway resistance and elastance when compared with control mice (Fig. 4A, 4B , respectively), indicating that these mice had AHR. In the same figure, we show that the intranasal IL-13-PE therapy from days 21-27 d postsilica decreased baseline levels of lung resistance and elastance and markedly reduced the AHR following methacholine provocation compared with untreated silicotic mice.
Intranasal administration of IL-13-PE diminished lung levels of cytokines and chemokines in silica-challenged mice
We next examined the effect of IL-13-PE therapy on lung secretion of pivotal inflammatory mediators in silicosis. In Fig. 5 , we show that lungs from silica-challenged mice after day 28 produced significantly more MIP-2 (Fig. 5A) , MIP-1a (Fig. 5B), MDC (Fig.  5C) , TARC (Fig. 5D) , as well as TNF-a (Fig. 5E ) and TGF-b (Fig. 5F ), than those from saline-challenged mice. In contrast, intranasal IL-13-PE therapy from days 21-27 markedly diminished levels of these proinflammatory and profibrotic cytokines in lung from silicotic mice (Fig. 5 ).
IL-13-PE treatment inhibited fibrosis after silica challenge
Next, we evaluated relevant constitutive proteins of extracellular matrix such as collagen fiber, laminin, and fibronectin. Histological analysis of whole lung showed that collagen fiber deposition in lungs from silica-exposed mice was significantly higher compared with the saline group (Fig. 6A, 6B) , and the IL-13-PE treatment was effective in reducing the collagen deposition (Fig. 6C ). For confirmation, we evaluated total collagen content in the lungs of silicotic animals and observed that collagen production was markedly reduced by IL-13-PE treatment (Fig. 6D) . Immunohistochemical analysis from silica-challenged mice showed a labeling for laminin (Fig. 6F) and fibronectin (Fig. 6J ), but little of the matrix components was observed in saline-challenge mice (Fig. 6E, 6I , respectively). The intranasal treatment with IL-13-PE, administered FIGURE 3. Picrosirius red-stained sections of mouse lungs after silica challenge and subsequently being given intranasal treatment with PBS-HSA (A) and IL-13-PE (B). Quantitative analysis of silica particles is seen in (C). H&E-stained sections of mediastinal lymph nodes of mouse challenge with saline (D), silica (E), and silica treated with IL-13-PE (F). Picrosirius red-stained sections of lymph nodes from silica challenge (G) and silica treated with IL-13-PE (H). Quantitative analysis of silica particles is seen in (I). All analyses were performed on day 28 after silica challenge. H&E-and Picrosirius red-stained sections were evaluated by light and polarized microscopy, respectively.
Asterisks and arrows indicate silica particles in (A), (B), and (E)-(H). Values represent mean 6
SEM from at least seven animals. Scale bars, 200 mm.*p , 0.05 as compared with silicachallenged group. every other day, from days 21-27 postsilica, strongly reduced labeling for both proteins (Fig. 6G, 6K , respectively). Quantitative morphometric analysis confirmed the efficacy of IL-13-PE therapy in the reduction of laminin (Fig. 6H ) and fibronectin ( Fig. 6L ) in silicotic mice.
IL-13-PE treatment significantly reduced the presence of macrophages and myofibroblasts cells in pulmonary granuloma
By immunohistochemical analysis, we examined the presence of macrophages and myofibroblasts in the lung tissue. We used F4/80 Ag for identification of macrophages and a-SMA for myofibroblasts. Initially, we observed that the lungs of saline-treated mice exhibited weaker labeling for F4/80 (Fig. 7A ) and a-SMA (Fig.  7E ) compared with silicotic mice (Fig. 7B, 7F , respectively). Both macrophages and myofibroblasts were sensitive to IL-13-PE therapy, as indicated by the reduction in labeling for F4/80 and a-SMA, respectively (Fig. 7C, 7G) . Quantitative data are shown in Fig. 7D and 7H.
IL-13-PE inhibits lung fibroblast proliferation and alveolar epithelial cell activation
Finally, the effect of IL-13-PE on fibroblasts and epithelial cells was analyzed in vitro. The direct effect of IL-13-PE on culture fibroblast proliferation is summarized in Fig. 8A . Cultured lung fibroblasts from silicotic mice showed an increase in the proliferation rate after IL-13 stimulation. The treatment with IL-13-PE (200 and 400 ng/ml), 1 h prior to stimulation with IL-13, significantly inhibited the enhanced proliferation induced by IL-13. No changes were observed in the proliferation rate of nontreated/ nonstimulated control cells (incubated with medium alone) and exposed only to IL-13-PE at 200 and 400 ng/ml (Fig 8A) . MTT assay was performed to evaluate the effect of IL-13-PE on the viability/proliferative response of fibroblasts from silicotic mice. Increased levels of MTT absorbance were detected in the condition of fibroblasts exposed to IL-13, and this effect was clearly sensitive to IL-13-PE (Fig 8B) . Additionally, the effect of IL-13-PE was tested on fibroblasts exposed to silica particles. In this case, lung fibroblasts from normal mice incubated with silica (30, 100 and 300 mg/ml) showed an increase in the MTT reduction, again sensitive to IL-13-PE (200 ng/ml) (Fig. 8C) . Similarly to what was noted with fibroblasts from silicotic mice, no cytotoxic effect of IL-13-PE was noted on control cells incubated only with medium (Fig. 8C ).
Regarding epithelial cell activation, A549 cells constitutively produce IL-8, and such basal secretion was increased when these cells were exposed to silica. Treatment with 200 and 400 ng/ml of IL-13-PE, 1 h prior to stimulation with silica, decreased IL-8 generation in a concentration-dependent manner (Fig. 9A) . As shown in Fig. 9B , there was no significant difference in cell viability between the cells of control group and cells treated with IL-13-PE alone. However, under condition of exposure to silica (300 mg/ml), a reduction of ∼40% in cell viability was noted. Incubation with IL-13-PE, 1 h prior to silica stimulation, clearly exacerbated the decrease in cell viability as compared with silica alone.
IL-13-PE treatment had no effect on airway epithelial cells in silicotic mice
As the human epithelial cell line A549 is a nonphysiological system, we extended our study to analyze the effect of IL-13-PE on respiratory epithelial cells in vivo. Apoptosis was assessed on lung tissue sections by TUNEL assay, which detects cells undergoing DNA fragmentation at relatively late stage of apoptosis. The results indicated that IL-13-PE treatment of silicotic mice did not alter the pattern of bronchiolar epithelium viability as compared with silicotic untreated mice, as shown in Fig. 9B and 9A, respectively. Positive control tissue treated with DNase I, before TUNEL assay, showed marked labeling of lung epithelial cells (data not shown). In contrast, a marked staining for TUNEL was detected in the lung parenchyma of silicotic mice (Fig. 10A) , indicating the presence of apoptotic cells associated with the granulomatous response. The phenomenon was inhibited by treatment with IL-13-PE (Fig. 10B) .
Discussion
In the current study, we investigated the sensitivity of silica-induced inflammatory and fibrogenic responses to a specific immunotoxin, IL-13-PE. Our results show that IL-13 levels and the receptors for this ligand (IL-13Ra1 and IL-13Ra2) and shared receptor IL-4Ra are upregulated following development of granulomatous lung inflammation caused by intranasal instillation of silica particles in mice. We demonstrate the therapeutic utility of targeting lung cells expressing IL-13R to reverse established pathological changes in this murine model of silicosis. In vitro, IL-13-PE directly prevented both silica-induced activation of the human alveolar type II epithelial cell lineage A549, as well as IL-13-induced proliferation of lung fibroblasts from mice exposed to silica particles. These findings suggest that the immunotoxin IL-13-PE can reduce pivotal lung pathological changes elicited by nasal-instilled silica in mice, suggesting that IL-13-PE might be a potential novel therapy for patients with silicosis.
Silicosis is a severe fibronodular disease of the lung parenchyma caused by inhalation of silica crystals (4) . Prior studies have provided considerable evidence that targeting the IL-13 pathway may be a way of controlling pulmonary inflammation and fibrosis, which are recognized as key pathological changes in a broad spectrum of respiratory diseases, including asthma (25), bronchiolitis obliterans syndrome (26) , and interstitial lung diseases (27) . In the current study, we detected increased levels of IL-13 in lung homogenates of mice exposed to silica particles 28 d postchallenge. In addition, immunohistochemistry analyses of lung sections obtained from these animals showed elevated expression of IL-4Ra, IL-13Ra1, and IL-13Ra2, as compared with lung samples from the negative controls, suggesting that IL-13 might be implicated in the lung fibrotic response to silica crystals. Remarkably, both IL-4 2/2 and IL-4Ra 2/2 mice are not protected against silica-induced lung inflammation and fibrosis (28) . Moreover, the IL-4Ra deficiency abolished IL-13Ra2 expression, leading to the interpretation that IL-13 could not compensate for IL-4 during the silicosis-like changes noted in IL-4Ra 2/2 mice (28). Although the role of Th2-like immune response in silicosis remains debatable, the IL-13Ra2 overexpression in silica-challenged wild-type mice, noted in the study by Misson and colleagues (28) and in this study, suggests that the involvement of IL-13 in the development of silicosis should not be discounted. In fact, in the current study, IL-13-responsive cells were targeted during the fibrotic phase when IL-13 clearly had an activating effect on lung structural cells. It is likely that the permanent (i.e., genetic) loss at IL-4 or IL-4Ra during the inflammatory phase in this model accounted for the lack of effect.
IL-13Ra2 has been identified as an attractive therapeutic target for several fibrotic diseases (27, (29) (30) (31) . The most prominent advantage of this molecular target is its specific overexpression under pathological conditions and its very low expression in the vast majority of healthy tissues (27) . Prior studies have shown that IL-13Ra2 binds IL-13 with high affinity and can internalize as a complex after binding the ligand (10). Husain and colleagues (32) took these properties into consideration to propose an alternative strategy of specifically targeting the IL-13 pathway using a chimeric IL-13-PE. It has been demonstrated that IL-13-PE can successfully eradicate not only IL-13R-positive tumors in vivo and in vitro (32) (33) (34) , but also established chronic airway inflammatory and fibrotic responses induced by distinct provocations, such as Aspergillus fumigatus (31), Schistosoma mansoni eggs (35) , and bleomycin (36) . Given the overexpression of IL-13Ra2 and IL-13 in silicotic mice, we addressed the hypothesis that the therapeutic treatment with IL-13-PE would impact inflammation and fibrosis in these animals. Quantitative morphometric analysis of lung histological sections revealed that, following silica exposure, the area occupied by granuloma increased progressively from days 2-28 postchallenge (data not shown), reaching ∼30% of the total lung parenchyma. Intranasal administration of IL-13-PE on alternate days from days 21-27 after silica exposure inhibited the granulomatous response 24 h after the last treatment, when IL-13 and its receptor subunits were clearly upregulated. Notably, the granuloma did remain significantly downregulated by at least 14 d after cessation of IL-13-PE treatment, suggesting that the immunotoxin indeed has an effective and long-lasting impact on the mechanism underlying . Viability of cultured lung fibroblast isolated from control mice (C). Cells were exposed to IL-13-PE (200 and 400 ng/ml) 24 h before stimulation with IL-13 (40 ng/ml) or silica particles (30, 100, and 300 mg/ml). Proliferation and viability (MTT) were monitored 24 h after stimulation. Values represent mean 6 SEM of quadruplicates from three independent experiments. + p , 0.05 compared with cells exposed to medium alone, *p , 0.05 compared with silica-stimulated cells (100 mg/ml), # p , 0.05 compared with silica-stimulated cells (300 mg/ml). silica-induced granuloma, similar to what was observed in case of S. mansoni egg-induced granuloma (35) .
The multiple fibronodular lesions in the context of clinical silicosis seem to result from the association into larger lesions of massive fibrotic response (4), which has been attributed to excess deposition of extracellular matrix components (37) . In the current study, increased deposition of collagen, fibronectin, and laminin was found in the lungs of silica-challenged mice, all of which were reversed by IL-13-PE treatment. Another prominent pathological feature of silicosis (also sensitive to IL-13-PE in this model) was the accumulation of a-SMA-positive fibroblasts into granulomatous area. Considerable attention has been directed toward the myofibroblast as a potential target of antifibrotic drugs because of its unique capacity to generate collagen and other matrix components (37, 38) . At this point, the precise identity of the IL-13-PE cell target remains unknown, but it is possible that this immunotoxin may act, at least in part, by reducing the number of myofibroblasts in the focus of the lesion. Accordingly, this may help to explain the marked reduction in the deposits of extracellular matrix, corresponding to the smaller granuloma formation noted in mice subjected to IL-13-PE treatment. Giving support to this interpretation, we demonstrated that IL-13-PE effectively inhibited IL-13-induced proliferation of cultured lung fibroblasts recovered from silicotic mice as tested by inhibition in [ 3 H]thymidine incorporation in vitro. It is noteworthy that the immunotoxin also prevented silica-induced fibroblast proliferation in vitro, indicating that silica particles themselves are not cytotoxic to lung fibroblasts. Similarly, IL-13-PE has been observed to inhibit directly the proliferative response of cultured pulmonary fibroblasts recovered from S. mansoni-challenged mice (35) .
Macrophages have been identified as pivotal regulators of fibrosis progression by functioning as phagocytic cells (38, 39) . Inhaled silica particles are indeed engulfed but not effectively cleared from the lungs by alveolar macrophages, causing persistent inflammation (40) . In this study, within 28 d postsilica, a high number of F4/80 + macrophages was found in the granuloma area, and this change appeared associated with increased levels of cytokines and chemokines, such as TNF-a, TGF-b, TARC, MDC, MIP-2, and MIP-1a. All of these changes were clearly sensitive to the therapeutic treatment with IL-13-PE, suggesting that the cascade of proinflammatory and profibrotic mediators generated by macrophages, and other cells, is inhibited following IL-13-PE. Although some conflicting reports about the effective role played by macrophages in animal models of silica-induced pulmonary fibrosis are identified (41) , there is convincing evidence of the silica-induced release of proinflammatory cytokines and chemokines from cultured alveolar monocytic cells and epithelial cells (42, 43) . In the current study, it has been shown that IL-13-PE effectively targeted silica-induced generation of IL-8 by human alveolar type II epithelial cell A549. Interestingly, despite the marked refractoriness of naive A549 cells to IL-13-PE, the chimeric toxin clearly exacerbated the cytotoxic effect of silica particles on A549 cells, as shown by the MTT assay, suggesting that the cytotoxic activity exerted by IL-13-PE was probably apparent only after silica-induced cell activation and subsequent IL-13R expression. Notably, the A549 cell line, which constitutively shows no IL-13Ra2 chain expression and little sensitivity to IL-13-PE, became sensitive to the immunotoxin following IL-13Ra2 transfection (44) . However, because the MTT assay is based on the measurement of mitochondrial enzyme activity, one cannot rule out the possibility that IL-13-PE reduces metabolic activity without affecting cell viability. While trying to clarify this point, and considering that a cytotoxic effect on lung structural cells might be a therapeutic disadvantage, we investigated the putative effect of IL-13-PE treatment on bronchiolar epithelial apoptosis/viability in vivo. Actually, silicotic mice treated with IL-13-PE showed no changes, as attested by the absence of TUNEL-positive apoptotic material in epithelium of bronchiolar sections. Nevertheless, a massive expression of apoptosis was detected in the granuloma area of untreated animals, which appeared clearly inhibited by IL-13-PE. It is important to point out that A549 is a human epithelial cell line, which may not represent the overall in vivo activity of IL-13-PE. Therefore, our in vivo results suggested that the immunosuppressive effect of IL-13-PE is not dependent on epithelial cell death.
It is noteworthy that IL-13-PE can reverse the overexpression of IL-13Rs following silica exposure, which might be an indicative of effective reduction of the inflammatory stimulus in the site of the lesion in this model. In fact, our findings revealed a significant reduction in the amount of free silica particles in the lung parenchyma of IL-13-PE-treated mice within 28 d after nasal instillation of silica. At the same time point, a marked tendency for elevation in silica particle numbers was observed in the lung mediastinal draining lymph node. Remarkably, evidence has been shown indicating that silicotic rats treated with cortisone also showed reduction of the amount of silica particles in the lungs and a little increase of silica detected in the lymph nodes (45) . It is known from patients that inhaled silica particles not only affect the lungs but also other organs, mainly mediastinal lymph nodes, although the underlying mechanism is still poorly understood (46) (47) (48) . Thus, it is conceivable that IL-13-PE might exert its inhibitory effect upon pulmonary silicosis, at least in part, by increasing the lymphaticmediated drainage of silica crystals from the lungs. Further studies are required to identify the mechanism accounting for the putative effect of IL-13-PE on silica particle clearance from the focus of the lesion, as well as to assess the putative detrimental side-effect impact of the silica transport to extrapulmonary sites.
Finally, prior studies have emphasized the condition of airflow limitation and AHR in patients with silicosis (49-51) and corresponding disease models (52) . Using invasive whole-body plethysmography, we demonstrated that the immunotoxin effectively reversed the state of unspecific AHR created by silica exposure, as attested by changes in both lung resistance and elastance following methacholine aerosolization. Because cytokines such as IL-13 and TNF-a, alone or in combination, have been strongly implicated in the mechanism of AHR (53-56), it seems reasonable to assume that the decrease in the generation and/or action of these mediators may be contributing to the IL-13-PE-dependent reduction in silicainduced AHR in this model. In addition, our data show a close correlation to the protective effect of IL-13-PE upon inflammation and fibrosis, as well as with the impairment of the accompanying AHR, suggesting a causative link among these events in experimental silicosis.
In conclusion, our findings uncover a novel putative therapeutic application for IL-13-PE by demonstrating the effectiveness of this immunotoxin in accelerating resolution of silica particle-induced pulmonary inflammation and fibrosis in silicotic mice. The evidence presented in this study also indicates that therapies aimed at targeting the IL-13/IL-13R pathway could benefit patients with silicosis.
